AI Analysis
AI-generated analysis. Always verify with the original filing.
Revenue was $1.3M (99.2%) Gross Profit was -$2.7M (-357.2%) Operating Income was -$7.5M (12.7%) Net Income was -$8.3M (-273.2%)
Key Takeaways
1Revenue increased 99% to $1.3M from $658K, reflecting CDMO services growth from expanded platform supporting wider customer needs.
2Gross loss expanded -357% to -$2.7M versus -$580K prior year as costs exceeded revenue in biologics manufacturing.
3Operating loss improved 12.7% to -$7.5M from -$8.6M due to decreased allocation of employees and facilities to R&D.
4Net loss of -$8.3M compared to $4.8M profit in 2024, reflecting absence of prior non-operating gains.
5Operating cash use of -$6.0M similar to prior -$6.3M, with minimal $24K capex emphasizing cash preservation.
6R&D strategy emphasizes capital efficiency, risk management, and optionality via internal platforms and external assets.